$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021008918 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$7.978M	$1.840M
YoY Change	333.59%	-98.73%
Cost Of Revenue	$1.800M	$0.00
YoY Change
Gross Profit	$6.200M	$1.800M
YoY Change	244.44%
Gross Profit Margin	77.71%	97.83%
Selling, General & Admin	$61.06M	$41.55M
YoY Change	46.95%	241.1%
% of Gross Profit	984.9%	2308.5%
Research & Development	$27.95M	$34.70M
YoY Change	-19.45%	-25.06%
% of Gross Profit	450.87%	1927.89%
Depreciation & Amortization	$153.0K	$106.0K
YoY Change	44.34%	49.3%
% of Gross Profit	2.47%	5.89%
Operating Expenses	$90.80M	$76.29M
YoY Change	19.03%	30.43%
Operating Profit	-$82.82M	-$74.45M
YoY Change	11.25%	-185.64%
Interest Expense	$8.125M	$4.171M
YoY Change	94.8%
% of Operating Profit
Other Income/Expense, Net	$14.00K	$368.0K
YoY Change	-96.2%	-18.22%
Pretax Income	-$90.90M	-$78.20M
YoY Change	16.24%	-189.47%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$90.94M	-$78.25M
YoY Change	16.21%	-189.55%
Net Earnings / Revenue	-1139.82%	-4252.66%
Basic Earnings Per Share	-$3.50	-$2.84
Diluted Earnings Per Share	-$3.50	-$2.84
COMMON SHARES
Basic Shares Outstanding	25.99M shares	27.52M shares
Diluted Shares Outstanding	25.99M shares	27.52M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$217.9M	$157.3M
YoY Change	38.51%	-31.15%
Cash & Equivalents	$217.9M	$149.4M
Short-Term Investments		$7.931M
Other Short-Term Assets	$12.40M	$13.40M
YoY Change	-7.46%	100.0%
Inventory	$20.03M	$1.841M
Prepaid Expenses
Receivables	$17.26M
Other Receivables	$5.000M
Total Short-Term Assets	$272.6M	$172.6M
YoY Change	57.9%	-26.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.123M	$1.447M
YoY Change	-22.39%	20.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.031M	$7.013M
YoY Change	-14.0%	439.46%
TOTAL ASSETS
Total Short-Term Assets	$272.6M	$172.6M
Total Long-Term Assets	$6.031M	$7.013M
Total Assets	$278.6M	$179.6M
YoY Change	55.09%	-24.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$30.34M	$15.11M
YoY Change	100.75%	-54.61%
Accrued Expenses	$58.70M	$48.20M
YoY Change	21.78%	111.4%
Deferred Revenue	$2.543M	$1.170M
YoY Change	117.35%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$97.89M	$73.45M
YoY Change	33.27%	22.42%
LONG-TERM LIABILITIES
Long-Term Debt	$271.7M	$0.00
YoY Change
Other Long-Term Liabilities	$1.290M	$156.4M
YoY Change	-99.18%	11071.43%
Total Long-Term Liabilities	$1.290M	$156.4M
YoY Change	-99.18%	11071.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$97.89M	$73.45M
Total Long-Term Liabilities	$1.290M	$156.4M
Total Liabilities	$548.0M	$229.9M
YoY Change	138.38%	273.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$928.2M	-$773.5M
YoY Change	20.0%
Common Stock	$26.00K	$28.00K
YoY Change	-7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$55.00M
YoY Change
Treasury Stock Shares	1.994M shares
Shareholders Equity	-$269.4M	-$50.25M
YoY Change
Total Liabilities & Shareholders Equity	$278.6M	$179.6M
YoY Change	55.09%	-24.04%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$90.94M	-$78.25M
YoY Change	16.21%	-189.55%
Depreciation, Depletion And Amortization	$153.0K	$106.0K
YoY Change	44.34%	49.3%
Cash From Operating Activities	-$89.07M	-$69.35M
YoY Change	28.44%	-175.63%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$191.0K
YoY Change	-100.0%	1.06%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$26.78M
YoY Change	-100.0%	-41.64%
Cash From Investing Activities	$0.00	$26.59M
YoY Change	-100.0%	-41.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.045M	$26.01M
YoY Change	-92.14%	1458.66%
NET CHANGE
Cash From Operating Activities	-$89.07M	-$69.35M
Cash From Investing Activities	$0.00	$26.59M
Cash From Financing Activities	$2.045M	$26.01M
Net Change In Cash	-$87.02M	-$16.74M
YoY Change	419.73%	-112.04%
FREE CASH FLOW
Cash From Operating Activities	-$89.07M	-$69.35M
Capital Expenditures	$0.00	$191.0K
Free Cash Flow	-$89.07M	-$69.54M
YoY Change	28.09%	-176.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	espr:AccountingStandardsUpdate202006Member
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-35986
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
CY2021Q1	dei	City Area Code CityAreaCode	734
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	887-3903
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	ESPR
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28192134	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	217939000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2021Q1	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	443000	USD
CY2020Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	844000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	20030000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34163000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23954000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	272575000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	345896000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1123000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1276000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4852000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6030000	USD
CY2021Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2021Q1	us-gaap	Assets Assets	278606000	USD
CY2020Q4	us-gaap	Assets Assets	353258000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	30342000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51975000	USD
CY2021Q1	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	7549000	USD
CY2020Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	7663000	USD
CY2021Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	48766000	USD
CY2020Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24790000	USD
CY2021Q1	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	6353000	USD
CY2020Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	5392000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2543000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1662000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2340000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	97893000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94069000	USD
CY2021Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	271694000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	179367000	USD
CY2021Q1	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	174603000	USD
CY2020Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	171212000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2520000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3454000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1290000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1290000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	548000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	449392000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28176917	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27910366	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	713782000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	797655000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-928204000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838817000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-269394000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	278606000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353258000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7978000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1840000	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1784000	USD
CY2020Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	31000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	27954000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34702000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61064000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41553000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	90802000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	76286000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-82824000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-74446000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	8125000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	4171000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	368000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.50
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.84
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25991817	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27519229	shares
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-14000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90935000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78263000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1014000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7053000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-50246000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2668000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1183000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5751000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-269394000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	153000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	106000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	73000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	400000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2021Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	4925000	USD
CY2020Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	4171000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5751000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7053000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9808000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2538000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	881000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-982000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3894000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1841000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21583000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-13650000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	25042000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	16656000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89068000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69347000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4420000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	31200000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	191000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26589000	USD
CY2021Q1	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	0	USD
CY2020Q1	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	25000000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2668000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1014000	USD
CY2021Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	573000	USD
CY2020Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	0	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	50000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2045000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26014000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-87023000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16744000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	217939000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150314000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	408000	USD
CY2021Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	4000	USD
CY2020Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	91000	USD
CY2021Q1	espr	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	445000	USD
CY2020Q1	espr	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March 31, 2021 and December 31, 2020, eight customers accounted for all of the Company's net trade receivables.</span></div>
CY2021Q1	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17505000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13788000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2078000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2028000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	447000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	320000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	20030000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	206804000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	206804000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	281783000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	281783000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	USD
CY2020Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	USD
CY2020Q4	espr	Revenue Interest Liability RevenueInterestLiability	176604000	USD
CY2021Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	573000	USD
CY2021Q1	espr	Revenue Interest Liability RevenueInterestLiability	180956000	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000.0	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000.0	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000.0	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000.0	USD
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17255000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12388000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18415000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	458000	shares
CY2021Q1	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	5000000	USD
CY2020Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	USD
CY2021Q1	espr	Prepaid Inventory Current PrepaidInventoryCurrent	7603000	USD
CY2020Q4	espr	Prepaid Inventory Current PrepaidInventoryCurrent	5957000	USD
CY2021Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4305000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	5609000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34163000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23954000	USD
CY2021Q1	us-gaap	Litigation Reserve LitigationReserve	18250000	USD
CY2020Q4	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11243000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15161000	USD
CY2021Q1	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	10082000	USD
CY2020Q4	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	5025000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4845000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3183000	USD
CY2021Q1	us-gaap	Interest Payable Current InterestPayableCurrent	4169000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1369000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52000	USD
CY2021Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	48766000	USD
CY2020Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24790000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4176518	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.24
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M10D
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	32.12
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	431675	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	54.06
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172268	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.49
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4030575	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.90
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19711000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4030575	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	38.90
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	19711000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3025257	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.81
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19711000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13148231	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5219216	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	217939000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149386000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q1	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	217939000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150314000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD

Files In Submission

Name	View Source	Status
0001628280-21-008918-index-headers.html	Edgar Link	pending
0001628280-21-008918-index.html	Edgar Link	pending
0001628280-21-008918.txt	Edgar Link	pending
0001628280-21-008918-xbrl.zip	Edgar Link	pending
espr-20210331.htm	Edgar Link	pending
espr-20210331.xsd	Edgar Link	pending
espr-20210331_cal.xml	Edgar Link	unprocessable
espr-20210331_def.xml	Edgar Link	unprocessable
espr-20210331_htm.xml	Edgar Link	completed
espr-20210331_lab.xml	Edgar Link	unprocessable
espr-20210331_pre.xml	Edgar Link	unprocessable
espr-ex311x03312021.htm	Edgar Link	pending
espr-ex312x03312021.htm	Edgar Link	pending
espr-ex321x03312021.htm	Edgar Link	pending
ex1012ndamendmentdseagreem.htm	Edgar Link	pending
ex31-secondamendedandresta.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2021 Q1 Form 10-Q Financial Statement

#000162828021008918 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2021 Q1 Form 10-Q Financial Statement

#000162828021008918 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr